JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU

Amarin is revving up to launch Vascepa into a cardiovascular market that could spell multibillion-dollar sales, and thanks to a major flop by AstraZeneca's would-be rival, Epanova—and a similar setback for Acasti Pharma—that U.S. launch has a runway clear of competitors. And in Europe, would-be partners want a piece of the action.